ORIGINAL RESEARCH article
Front. Vet. Sci.
Sec. Veterinary Pharmacology and Toxicology
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1576669
Pharmacokinetic Evaluation and Bioavailability of KPT-335 (Verdinexor) in Cats
Provisionally accepted
- 1China Agricultural University, Beijing, China
- 2Shanxi Agricultural University, Jinzhong, Shanxi Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
KPT-335 (Verdinexor) is a novel, orally bioavailable selective inhibitor of nuclear export that has gained significant attention in pharmaceutical research due to its potential anti-tumor and antiviral effects. This study aimed to evaluate the pharmacokinetic parameters and determine the absolute bioavailability of KPT-335 through various administration routes, including oral capsules and tablets, along with intravenous injections. The intravenous group received a dosage of 1 mg/kg body weight (BW), while capsules were administered orally at doses of 0.2, 1, and 2 mg/kg BW. Tablets were also administered orally at 1 and 2 mg/kg BW, with both post-feeding and fasting conditions at the 1 mg/kg BW dosage. Plasma concentrations of KPT-335 were analyzed using ultra-performance liquid chromatography/tandem mass spectrometry. Key pharmacokinetic parameters, including peak concentration (Cmax), area under the curve (AUC0–last), and terminal phase elimination half-life (T1/2), were determined through non-compartmental analysis using WinNonlin 8.1. The absolute bioavailability rates of 43.72%, 44.66%, and 28.92% for the low, medium, and high-dose capsule groups, respectively. In the tablet formulation, bioavailability at 1 mg/kg BW (fasting), 1 mg/kg BW (feeding), and 2 mg/kg BW (feeding) were 75.92%, 70.98%, and 47.27%,, respectively. KPT-335 demonstrated pharmacokinetic characteristics of rapid absorption and elimination. The results demonstrated that KPT-335 exhibited non-linear pharmacokinetic behavior, indicating that higher doses are not fully absorbed in cats. This finding provides data support for guiding clinical dosing regimens. At the same dose, the absolute bioavailability of the tablet group was higher than that of the capsule group.
Keywords: KPT-335, pharmacokinetic, bioavailability, cat, Plasma
Received: 14 Feb 2025; Accepted: 21 Apr 2025.
Copyright: © 2025 Yang, Meng, Wen, Wang and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yuxin Yang, China Agricultural University, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.